Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)

BACKGROUND: Chemotherapy with biologics followed by liver surgery improves the resection rate and survival of patients with colorectal liver metastasis (CRLM). However, no prospective study has compared the outcomes of chemotherapy with bevacizumab (BEV) versus cetuximab (CET). METHODS: The ATOM stu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Oki, Eiji, Emi, Yasunori, Yamanaka, Takeharu, Uetake, Hiroyuki, Muro, Kei, Takahashi, Takao, Nagasaka, Takeshi, Hatano, Etsuro, Ojima, Hitoshi, Manaka, Dai, Kusumoto, Tetsuya, Katayose, Yu, Fujiwara, Toshiyoshi, Yoshida, Kazuhiro, Unno, Michiaki, Hyodo, Ichinosuke, Tomita, Naohiro, Sugihara, Kenichi, Maehara, Yoshihiko
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6738101/
https://ncbi.nlm.nih.gov/pubmed/31285591
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0518-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados